Morgan Stanley lowered the firm’s price target on Amgen to $281 from $291 and keeps an Equal Weight rating on the shares. In offering a 2024 outlook for North American Biopharma, the firm says it expects four themes – diabesity, product cycles, policy and rates – to be in focus next year. At the stock level, the firm expects “another year of dispersion” and generally recommends investors continue to focus on companies that can deliver growth in the second half of the decade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMGN:
- Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer — Here Are 2 Stocks to Take Advantage
- ‘From Hype to Clinical‘: Cowen Suggests 2 AI Healthcare Stocks to Consider
- Amgen receives Orphan Drug Designation for treatment of biliary tract cancers
- Amgen (NASDAQ:AMGN) Gains on New AWS Partnership
- Fly Insider: Air Products, Amgen among this week’s notable insider trades